This review summarizes the efficacy and safety profile of edoxaban in patients with nonvalvular atrial fibrillation from preclinical development through phase III trials.
Answers are grounded in this paper and cite their sources.
Consolidates edoxaban trial data for nonvalvular AF; leaves open need for updated comparative effectiveness studies.
Edoxaban, a direct factor Xa inhibitor, was extensively studied in the prevention and treatment of venous thromboembolism and in patients with nonvalvular atrial fibrillation (AF). The aim of this review is to focus specifically on the efficacy and safety profile of edoxaban in patients with AF from preclinical development through the phase III trial that led to regulatory approval.
No takes yet. Share an insight, caveat, or question.
Eisen et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: